These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
13. Immunohistochemical pattern of p53 is a measure of TP53 mutation burden and adverse clinical outcome in myelodysplastic syndromes and secondary acute myeloid leukemia. McGraw KL; Nguyen J; Komrokji RS; Sallman D; Al Ali NH; Padron E; Lancet JE; Moscinski LC; List AF; Zhang L Haematologica; 2016 Aug; 101(8):e320-3. PubMed ID: 27081179 [No Abstract] [Full Text] [Related]
14. KIT mutations correlate with adverse survival in children with core-binding factor acute myeloid leukemia. Chen X; Dou H; Wang X; Huang Y; Lu L; Bin J; Su Y; Zou L; Yu J; Bao L Leuk Lymphoma; 2018 Apr; 59(4):829-836. PubMed ID: 28792268 [TBL] [Abstract][Full Text] [Related]
15. Inactivation of the p53-KLF4-CEBPA Axis in Acute Myeloid Leukemia. Seipel K; Marques MT; Bozzini MA; Meinken C; Mueller BU; Pabst T Clin Cancer Res; 2016 Feb; 22(3):746-56. PubMed ID: 26408402 [TBL] [Abstract][Full Text] [Related]
16. Core-binding factor acute myeloid leukemia: Heterogeneity, monitoring, and therapy. Solh M; Yohe S; Weisdorf D; Ustun C Am J Hematol; 2014 Dec; 89(12):1121-31. PubMed ID: 25088818 [TBL] [Abstract][Full Text] [Related]
18. The role of p53 in myelodysplastic syndromes and acute myeloid leukemia: molecular aspects and clinical implications. Zhang L; McGraw KL; Sallman DA; List AF Leuk Lymphoma; 2017 Aug; 58(8):1777-1790. PubMed ID: 27967292 [TBL] [Abstract][Full Text] [Related]
19. Current status and new treatment approaches in TP53 mutated AML. Hunter AM; Sallman DA Best Pract Res Clin Haematol; 2019 Jun; 32(2):134-144. PubMed ID: 31203995 [TBL] [Abstract][Full Text] [Related]